Rituximab modulated retinal atrophy in relapsing-remitting MS, with attenuating effects that may be more significant after 12 months of treatment, according to results of an observational study published in Neurology.
“Many experts purport that therapeutic optimization occurs rapidly following the commencement of B-cell-depleting disease-modifying treatment of relapsing-remitting MS [RRMS],” Shiv Saidha, MBBCh, MD, MRCPI, lead author and professor of neurology at the Johns Hopkins University School of Medicine, told Healio Neurology. “However, there is a suggestion in the